Your browser doesn't support javascript.
loading
Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.
Nghiem-Buffet, S; Baillif, S; Regnier, S; Skelly, A; Yu, N; Sodi, A.
Affiliation
  • Nghiem-Buffet S; Centre Ophtalmologique d'Imagerie et de Laser, Paris, France.
  • Baillif S; Department of Ophthalmology, Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France.
  • Regnier S; Department of Ophthalmology, Pasteur II University Hospital, Nice, France.
  • Skelly A; Novartis Pharma AG, Basel, Switzerland.
  • Yu N; Novartis Ireland Limited, Dublin, Ireland.
  • Sodi A; Real-World Evidence Solutions, IMS Health, London, UK.
Eye (Lond) ; 31(7): 1113-1114, 2017 07.
Article in En | MEDLINE | ID: mdl-28234353
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retinal Vein Occlusion / Ranibizumab Limits: Humans Language: En Journal: Eye (Lond) Journal subject: OFTALMOLOGIA Year: 2017 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retinal Vein Occlusion / Ranibizumab Limits: Humans Language: En Journal: Eye (Lond) Journal subject: OFTALMOLOGIA Year: 2017 Document type: Article Affiliation country: Country of publication: